nodes	percent_of_prediction	percent_of_DWPC	metapath
Icosapent—ACSL4—prostate cancer	0.63	0.931	CbGaD
Icosapent—PTGS2—prostate cancer	0.0464	0.0686	CbGaD
Icosapent—ACSL3—prostate gland—prostate cancer	0.00618	0.0915	CbGeAlD
Icosapent—ACSL3—renal system—prostate cancer	0.00421	0.0624	CbGeAlD
Icosapent—SLC8A1—renal system—prostate cancer	0.00349	0.0517	CbGeAlD
Icosapent—FADS1—prostate gland—prostate cancer	0.00342	0.0506	CbGeAlD
Icosapent—ACSL4—prostate gland—prostate cancer	0.0031	0.046	CbGeAlD
Icosapent—PPARD—prostate gland—prostate cancer	0.00298	0.0441	CbGeAlD
Icosapent—FADS1—seminal vesicle—prostate cancer	0.00289	0.0428	CbGeAlD
Icosapent—ACSL3—testis—prostate cancer	0.00272	0.0403	CbGeAlD
Icosapent—ACSL4—seminal vesicle—prostate cancer	0.00263	0.0389	CbGeAlD
Icosapent—TRPV1—epithelium—prostate cancer	0.00251	0.0372	CbGeAlD
Icosapent—TRPV1—renal system—prostate cancer	0.00233	0.0345	CbGeAlD
Icosapent—FADS1—urethra—prostate cancer	0.00229	0.0339	CbGeAlD
Icosapent—ACSL4—renal system—prostate cancer	0.00212	0.0313	CbGeAlD
Icosapent—ACSL4—urethra—prostate cancer	0.00208	0.0308	CbGeAlD
Icosapent—Oropharyngeal pain—Cabazitaxel—prostate cancer	0.00203	0.0241	CcSEcCtD
Icosapent—FADS1—bone marrow—prostate cancer	0.00176	0.0261	CbGeAlD
Icosapent—ACSL4—bone marrow—prostate cancer	0.0016	0.0237	CbGeAlD
Icosapent—PPARG—Teniposide—Etoposide—prostate cancer	0.00158	1	CbGdCrCtD
Icosapent—Aspartate aminotransferase increased—Abiraterone—prostate cancer	0.00157	0.0186	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Abiraterone—prostate cancer	0.00154	0.0182	CcSEcCtD
Icosapent—FADS1—testis—prostate cancer	0.00151	0.0223	CbGeAlD
Icosapent—TRPV1—testis—prostate cancer	0.00151	0.0223	CbGeAlD
Icosapent—Aspartate aminotransferase increased—Nilutamide—prostate cancer	0.00144	0.017	CcSEcCtD
Icosapent—Aspartate aminotransferase increased—Flutamide—prostate cancer	0.00143	0.0169	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Nilutamide—prostate cancer	0.00141	0.0167	CcSEcCtD
Icosapent—PPARG—prostate gland—prostate cancer	0.0014	0.0207	CbGeAlD
Icosapent—ACSL4—testis—prostate cancer	0.00137	0.0202	CbGeAlD
Icosapent—PPARD—testis—prostate cancer	0.00131	0.0194	CbGeAlD
Icosapent—Aspartate aminotransferase increased—Cabazitaxel—prostate cancer	0.00121	0.0143	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Cabazitaxel—prostate cancer	0.00118	0.014	CcSEcCtD
Icosapent—FADS1—lymph node—prostate cancer	0.00109	0.0162	CbGeAlD
Icosapent—Aspartate aminotransferase increased—Bicalutamide—prostate cancer	0.00104	0.0123	CcSEcCtD
Icosapent—PPARG—epithelium—prostate cancer	0.00103	0.0152	CbGeAlD
Icosapent—Alanine aminotransferase increased—Bicalutamide—prostate cancer	0.00102	0.012	CcSEcCtD
Icosapent—ACSL4—lymph node—prostate cancer	0.000991	0.0147	CbGeAlD
Icosapent—PPARG—renal system—prostate cancer	0.000952	0.0141	CbGeAlD
Icosapent—PPARD—lymph node—prostate cancer	0.000952	0.0141	CbGeAlD
Icosapent—PPARG—urethra—prostate cancer	0.000935	0.0138	CbGeAlD
Icosapent—Malnutrition—Estradiol valerate/Dienogest—prostate cancer	0.000902	0.0107	CcSEcCtD
Icosapent—Arthralgia—Estrone—prostate cancer	0.00088	0.0104	CcSEcCtD
Icosapent—Malnutrition—Degarelix—prostate cancer	0.000858	0.0102	CcSEcCtD
Icosapent—Anaphylactic shock—Estrone—prostate cancer	0.000844	0.01	CcSEcCtD
Icosapent—Malnutrition—Cabazitaxel—prostate cancer	0.000808	0.00957	CcSEcCtD
Icosapent—Dysgeusia—Cabazitaxel—prostate cancer	0.000791	0.00938	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Abiraterone—prostate cancer	0.000782	0.00926	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Estrone—prostate cancer	0.000769	0.00911	CcSEcCtD
Icosapent—Dyspepsia—Abiraterone—prostate cancer	0.000755	0.00895	CcSEcCtD
Icosapent—PTGS1—prostate gland—prostate cancer	0.000747	0.0111	CbGeAlD
Icosapent—Gastrointestinal disorder—Abiraterone—prostate cancer	0.000741	0.00877	CcSEcCtD
Icosapent—Anaphylactic shock—Estradiol valerate/Dienogest—prostate cancer	0.000736	0.00872	CcSEcCtD
Icosapent—Constipation—Abiraterone—prostate cancer	0.000734	0.00869	CcSEcCtD
Icosapent—Arthralgia—Degarelix—prostate cancer	0.00073	0.00865	CcSEcCtD
Icosapent—PPARG—bone marrow—prostate cancer	0.00072	0.0107	CbGeAlD
Icosapent—PTGS2—prostate gland—prostate cancer	0.000714	0.0106	CbGeAlD
Icosapent—Anaphylactic shock—Degarelix—prostate cancer	0.0007	0.00829	CcSEcCtD
Icosapent—Malnutrition—Bicalutamide—prostate cancer	0.000693	0.00821	CcSEcCtD
Icosapent—Dyspepsia—Nilutamide—prostate cancer	0.00069	0.00817	CcSEcCtD
Icosapent—Arthralgia—Cabazitaxel—prostate cancer	0.000688	0.00815	CcSEcCtD
Icosapent—Gastrointestinal disorder—Nilutamide—prostate cancer	0.000677	0.00802	CcSEcCtD
Icosapent—Constipation—Nilutamide—prostate cancer	0.00067	0.00794	CcSEcCtD
Icosapent—Constipation—Flutamide—prostate cancer	0.000667	0.0079	CcSEcCtD
Icosapent—Dyspepsia—Estradiol valerate/Dienogest—prostate cancer	0.000648	0.00768	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Degarelix—prostate cancer	0.000638	0.00756	CcSEcCtD
Icosapent—Gastrointestinal disorder—Estradiol valerate/Dienogest—prostate cancer	0.000636	0.00753	CcSEcCtD
Icosapent—PTGS1—seminal vesicle—prostate cancer	0.000631	0.00935	CbGeAlD
Icosapent—Pruritus—Estramustine—prostate cancer	0.000625	0.0074	CcSEcCtD
Icosapent—Oropharyngeal pain—Docetaxel—prostate cancer	0.000619	0.00734	CcSEcCtD
Icosapent—PPARG—testis—prostate cancer	0.000615	0.00911	CbGeAlD
Icosapent—Gastrointestinal disorder—Degarelix—prostate cancer	0.000604	0.00716	CcSEcCtD
Icosapent—PTGS2—seminal vesicle—prostate cancer	0.000604	0.00894	CbGeAlD
Icosapent—Musculoskeletal discomfort—Cabazitaxel—prostate cancer	0.000601	0.00712	CcSEcCtD
Icosapent—Oropharyngeal pain—Capecitabine—prostate cancer	0.0006	0.00711	CcSEcCtD
Icosapent—Constipation—Degarelix—prostate cancer	0.000599	0.00709	CcSEcCtD
Icosapent—Pruritus—Estrone—prostate cancer	0.000597	0.00707	CcSEcCtD
Icosapent—Malnutrition—Ethinyl Estradiol—prostate cancer	0.000586	0.00694	CcSEcCtD
Icosapent—Dyspepsia—Cabazitaxel—prostate cancer	0.000581	0.00688	CcSEcCtD
Icosapent—Gastrointestinal disorder—Cabazitaxel—prostate cancer	0.000569	0.00675	CcSEcCtD
Icosapent—Constipation—Cabazitaxel—prostate cancer	0.000564	0.00668	CcSEcCtD
Icosapent—Vomiting—Estramustine—prostate cancer	0.000562	0.00665	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Estradiol—prostate cancer	0.00056	0.00663	CcSEcCtD
Icosapent—Rash—Estramustine—prostate cancer	0.000557	0.0066	CcSEcCtD
Icosapent—Dermatitis—Estramustine—prostate cancer	0.000556	0.00659	CcSEcCtD
Icosapent—Pruritus—Nilutamide—prostate cancer	0.000555	0.00657	CcSEcCtD
Icosapent—Pruritus—Flutamide—prostate cancer	0.000552	0.00654	CcSEcCtD
Icosapent—PTGS1—epithelium—prostate cancer	0.000549	0.00812	CbGeAlD
Icosapent—Vomiting—Abiraterone—prostate cancer	0.000545	0.00646	CcSEcCtD
Icosapent—Rash—Abiraterone—prostate cancer	0.000541	0.00641	CcSEcCtD
Icosapent—Dermatitis—Abiraterone—prostate cancer	0.00054	0.0064	CcSEcCtD
Icosapent—Vomiting—Estrone—prostate cancer	0.000537	0.00636	CcSEcCtD
Icosapent—Aspartate aminotransferase increased—Mitoxantrone—prostate cancer	0.000533	0.00631	CcSEcCtD
Icosapent—Rash—Estrone—prostate cancer	0.000532	0.0063	CcSEcCtD
Icosapent—Dermatitis—Estrone—prostate cancer	0.000532	0.0063	CcSEcCtD
Icosapent—PTGS2—epithelium—prostate cancer	0.000524	0.00776	CbGeAlD
Icosapent—Alanine aminotransferase increased—Mitoxantrone—prostate cancer	0.000522	0.00618	CcSEcCtD
Icosapent—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.000521	0.00617	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Bicalutamide—prostate cancer	0.000516	0.00611	CcSEcCtD
Icosapent—PTGS1—renal system—prostate cancer	0.000509	0.00753	CbGeAlD
Icosapent—Vomiting—Nilutamide—prostate cancer	0.000498	0.0059	CcSEcCtD
Icosapent—Dyspepsia—Bicalutamide—prostate cancer	0.000498	0.0059	CcSEcCtD
Icosapent—Vomiting—Flutamide—prostate cancer	0.000496	0.00588	CcSEcCtD
Icosapent—Pruritus—Degarelix—prostate cancer	0.000495	0.00587	CcSEcCtD
Icosapent—Rash—Nilutamide—prostate cancer	0.000494	0.00585	CcSEcCtD
Icosapent—Dermatitis—Nilutamide—prostate cancer	0.000494	0.00585	CcSEcCtD
Icosapent—Rash—Flutamide—prostate cancer	0.000492	0.00583	CcSEcCtD
Icosapent—Dermatitis—Flutamide—prostate cancer	0.000492	0.00582	CcSEcCtD
Icosapent—Gastrointestinal disorder—Bicalutamide—prostate cancer	0.000488	0.00579	CcSEcCtD
Icosapent—PTGS2—renal system—prostate cancer	0.000486	0.0072	CbGeAlD
Icosapent—Constipation—Bicalutamide—prostate cancer	0.000484	0.00573	CcSEcCtD
Icosapent—Malnutrition—Goserelin—prostate cancer	0.000482	0.00571	CcSEcCtD
Icosapent—PTGS2—urethra—prostate cancer	0.000478	0.00707	CbGeAlD
Icosapent—Malnutrition—Conjugated Estrogens—prostate cancer	0.000478	0.00566	CcSEcCtD
Icosapent—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.000468	0.00555	CcSEcCtD
Icosapent—Dysgeusia—Conjugated Estrogens—prostate cancer	0.000468	0.00554	CcSEcCtD
Icosapent—Rash—Estradiol valerate/Dienogest—prostate cancer	0.000464	0.0055	CcSEcCtD
Icosapent—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.000464	0.0055	CcSEcCtD
Icosapent—PPARG—lymph node—prostate cancer	0.000446	0.0066	CbGeAlD
Icosapent—Vomiting—Degarelix—prostate cancer	0.000445	0.00527	CcSEcCtD
Icosapent—Rash—Degarelix—prostate cancer	0.000441	0.00523	CcSEcCtD
Icosapent—Dermatitis—Degarelix—prostate cancer	0.000441	0.00523	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Etoposide—prostate cancer	0.000434	0.00514	CcSEcCtD
Icosapent—Vomiting—Cabazitaxel—prostate cancer	0.000419	0.00497	CcSEcCtD
Icosapent—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.000413	0.00489	CcSEcCtD
Icosapent—Arthralgia—Goserelin—prostate cancer	0.000411	0.00486	CcSEcCtD
Icosapent—Constipation—Ethinyl Estradiol—prostate cancer	0.000409	0.00485	CcSEcCtD
Icosapent—Arthralgia—Conjugated Estrogens—prostate cancer	0.000407	0.00482	CcSEcCtD
Icosapent—Pruritus—Bicalutamide—prostate cancer	0.0004	0.00474	CcSEcCtD
Icosapent—Anaphylactic shock—Goserelin—prostate cancer	0.000394	0.00466	CcSEcCtD
Icosapent—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.00039	0.00462	CcSEcCtD
Icosapent—Malnutrition—Estradiol—prostate cancer	0.000382	0.00453	CcSEcCtD
Icosapent—Dysgeusia—Estradiol—prostate cancer	0.000374	0.00444	CcSEcCtD
Icosapent—Eructation—Epirubicin—prostate cancer	0.000373	0.00442	CcSEcCtD
Icosapent—Aspartate aminotransferase increased—Docetaxel—prostate cancer	0.000368	0.00436	CcSEcCtD
Icosapent—PTGS2—bone marrow—prostate cancer	0.000368	0.00544	CbGeAlD
Icosapent—Alanine aminotransferase increased—Docetaxel—prostate cancer	0.000361	0.00427	CcSEcCtD
Icosapent—Vomiting—Bicalutamide—prostate cancer	0.00036	0.00426	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Goserelin—prostate cancer	0.000359	0.00425	CcSEcCtD
Icosapent—Rash—Bicalutamide—prostate cancer	0.000357	0.00423	CcSEcCtD
Icosapent—Aspartate aminotransferase increased—Capecitabine—prostate cancer	0.000357	0.00422	CcSEcCtD
Icosapent—Dermatitis—Bicalutamide—prostate cancer	0.000356	0.00422	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Conjugated Estrogens—prostate cancer	0.000355	0.00421	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Capecitabine—prostate cancer	0.000349	0.00414	CcSEcCtD
Icosapent—Dysgeusia—Mitoxantrone—prostate cancer	0.000349	0.00413	CcSEcCtD
Icosapent—Dyspepsia—Goserelin—prostate cancer	0.000346	0.0041	CcSEcCtD
Icosapent—Eructation—Doxorubicin—prostate cancer	0.000345	0.00409	CcSEcCtD
Icosapent—Dyspepsia—Conjugated Estrogens—prostate cancer	0.000343	0.00407	CcSEcCtD
Icosapent—Pruritus—Ethinyl Estradiol—prostate cancer	0.000338	0.00401	CcSEcCtD
Icosapent—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000337	0.00399	CcSEcCtD
Icosapent—Constipation—Goserelin—prostate cancer	0.000337	0.00399	CcSEcCtD
Icosapent—Constipation—Conjugated Estrogens—prostate cancer	0.000333	0.00395	CcSEcCtD
Icosapent—PTGS1—testis—prostate cancer	0.000329	0.00487	CbGeAlD
Icosapent—Arthralgia—Estradiol—prostate cancer	0.000325	0.00386	CcSEcCtD
Icosapent—Anaphylactic shock—Estradiol—prostate cancer	0.000312	0.0037	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Prednisone—prostate cancer	0.000311	0.00368	CcSEcCtD
Icosapent—Vomiting—Ethinyl Estradiol—prostate cancer	0.000304	0.0036	CcSEcCtD
Icosapent—Arthralgia—Mitoxantrone—prostate cancer	0.000303	0.00359	CcSEcCtD
Icosapent—Rash—Ethinyl Estradiol—prostate cancer	0.000302	0.00357	CcSEcCtD
Icosapent—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000301	0.00357	CcSEcCtD
Icosapent—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000291	0.00344	CcSEcCtD
Icosapent—Dysgeusia—Etoposide—prostate cancer	0.00029	0.00344	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Estradiol—prostate cancer	0.000284	0.00337	CcSEcCtD
Icosapent—Pruritus—Goserelin—prostate cancer	0.000278	0.0033	CcSEcCtD
Icosapent—Pruritus—Conjugated Estrogens—prostate cancer	0.000276	0.00327	CcSEcCtD
Icosapent—Dyspepsia—Estradiol—prostate cancer	0.000275	0.00325	CcSEcCtD
Icosapent—Gastrointestinal disorder—Estradiol—prostate cancer	0.000269	0.00319	CcSEcCtD
Icosapent—Constipation—Estradiol—prostate cancer	0.000267	0.00316	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000265	0.00314	CcSEcCtD
Icosapent—Dyspepsia—Mitoxantrone—prostate cancer	0.000256	0.00303	CcSEcCtD
Icosapent—Vomiting—Goserelin—prostate cancer	0.00025	0.00296	CcSEcCtD
Icosapent—Constipation—Mitoxantrone—prostate cancer	0.000249	0.00295	CcSEcCtD
Icosapent—Aspartate aminotransferase increased—Epirubicin—prostate cancer	0.000248	0.00294	CcSEcCtD
Icosapent—Rash—Goserelin—prostate cancer	0.000248	0.00294	CcSEcCtD
Icosapent—Dermatitis—Goserelin—prostate cancer	0.000248	0.00294	CcSEcCtD
Icosapent—Vomiting—Conjugated Estrogens—prostate cancer	0.000248	0.00294	CcSEcCtD
Icosapent—Malnutrition—Docetaxel—prostate cancer	0.000246	0.00292	CcSEcCtD
Icosapent—Rash—Conjugated Estrogens—prostate cancer	0.000246	0.00291	CcSEcCtD
Icosapent—Dermatitis—Conjugated Estrogens—prostate cancer	0.000246	0.00291	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Epirubicin—prostate cancer	0.000243	0.00288	CcSEcCtD
Icosapent—Anaphylactic shock—Etoposide—prostate cancer	0.000242	0.00286	CcSEcCtD
Icosapent—Dysgeusia—Docetaxel—prostate cancer	0.000241	0.00286	CcSEcCtD
Icosapent—Malnutrition—Capecitabine—prostate cancer	0.000238	0.00282	CcSEcCtD
Icosapent—PTGS1—lymph node—prostate cancer	0.000238	0.00353	CbGeAlD
Icosapent—Dysgeusia—Capecitabine—prostate cancer	0.000233	0.00277	CcSEcCtD
Icosapent—Aspartate aminotransferase increased—Doxorubicin—prostate cancer	0.00023	0.00272	CcSEcCtD
Icosapent—PTGS2—lymph node—prostate cancer	0.000228	0.00337	CbGeAlD
Icosapent—Alanine aminotransferase increased—Doxorubicin—prostate cancer	0.000225	0.00267	CcSEcCtD
Icosapent—Pruritus—Estradiol—prostate cancer	0.000221	0.00262	CcSEcCtD
Icosapent—Malnutrition—Prednisone—prostate cancer	0.000212	0.00252	CcSEcCtD
Icosapent—Arthralgia—Docetaxel—prostate cancer	0.00021	0.00248	CcSEcCtD
Icosapent—Gastrointestinal disorder—Etoposide—prostate cancer	0.000209	0.00247	CcSEcCtD
Icosapent—Constipation—Etoposide—prostate cancer	0.000207	0.00245	CcSEcCtD
Icosapent—Arthralgia—Capecitabine—prostate cancer	0.000203	0.0024	CcSEcCtD
Icosapent—Anaphylactic shock—Docetaxel—prostate cancer	0.000201	0.00238	CcSEcCtD
Icosapent—Vomiting—Estradiol—prostate cancer	0.000198	0.00235	CcSEcCtD
Icosapent—Rash—Estradiol—prostate cancer	0.000197	0.00233	CcSEcCtD
Icosapent—Dermatitis—Estradiol—prostate cancer	0.000197	0.00233	CcSEcCtD
Icosapent—Vomiting—Mitoxantrone—prostate cancer	0.000185	0.00219	CcSEcCtD
Icosapent—Rash—Mitoxantrone—prostate cancer	0.000183	0.00217	CcSEcCtD
Icosapent—Dermatitis—Mitoxantrone—prostate cancer	0.000183	0.00217	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000183	0.00217	CcSEcCtD
Icosapent—Arthralgia—Prednisone—prostate cancer	0.000181	0.00214	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000177	0.0021	CcSEcCtD
Icosapent—Dyspepsia—Docetaxel—prostate cancer	0.000177	0.0021	CcSEcCtD
Icosapent—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000174	0.00206	CcSEcCtD
Icosapent—Anaphylactic shock—Prednisone—prostate cancer	0.000173	0.00205	CcSEcCtD
Icosapent—Constipation—Docetaxel—prostate cancer	0.000172	0.00204	CcSEcCtD
Icosapent—Dyspepsia—Capecitabine—prostate cancer	0.000171	0.00203	CcSEcCtD
Icosapent—Pruritus—Etoposide—prostate cancer	0.000171	0.00203	CcSEcCtD
Icosapent—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000168	0.00199	CcSEcCtD
Icosapent—Constipation—Capecitabine—prostate cancer	0.000166	0.00197	CcSEcCtD
Icosapent—Malnutrition—Epirubicin—prostate cancer	0.000166	0.00197	CcSEcCtD
Icosapent—Dysgeusia—Epirubicin—prostate cancer	0.000163	0.00193	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000158	0.00187	CcSEcCtD
Icosapent—Vomiting—Etoposide—prostate cancer	0.000154	0.00182	CcSEcCtD
Icosapent—Malnutrition—Doxorubicin—prostate cancer	0.000154	0.00182	CcSEcCtD
Icosapent—Dyspepsia—Prednisone—prostate cancer	0.000153	0.00181	CcSEcCtD
Icosapent—Rash—Etoposide—prostate cancer	0.000152	0.00181	CcSEcCtD
Icosapent—Dermatitis—Etoposide—prostate cancer	0.000152	0.0018	CcSEcCtD
Icosapent—Dysgeusia—Doxorubicin—prostate cancer	0.000151	0.00178	CcSEcCtD
Icosapent—Constipation—Prednisone—prostate cancer	0.000148	0.00176	CcSEcCtD
Icosapent—Pruritus—Docetaxel—prostate cancer	0.000142	0.00168	CcSEcCtD
Icosapent—Arthralgia—Epirubicin—prostate cancer	0.000141	0.00168	CcSEcCtD
Icosapent—Pruritus—Capecitabine—prostate cancer	0.000138	0.00163	CcSEcCtD
Icosapent—Anaphylactic shock—Epirubicin—prostate cancer	0.000136	0.00161	CcSEcCtD
Icosapent—Arthralgia—Doxorubicin—prostate cancer	0.000131	0.00155	CcSEcCtD
Icosapent—Vomiting—Docetaxel—prostate cancer	0.000128	0.00151	CcSEcCtD
Icosapent—Rash—Docetaxel—prostate cancer	0.000127	0.0015	CcSEcCtD
Icosapent—Dermatitis—Docetaxel—prostate cancer	0.000127	0.0015	CcSEcCtD
Icosapent—Anaphylactic shock—Doxorubicin—prostate cancer	0.000125	0.00149	CcSEcCtD
Icosapent—Vomiting—Capecitabine—prostate cancer	0.000124	0.00147	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000124	0.00146	CcSEcCtD
Icosapent—Rash—Capecitabine—prostate cancer	0.000123	0.00145	CcSEcCtD
Icosapent—Pruritus—Prednisone—prostate cancer	0.000123	0.00145	CcSEcCtD
Icosapent—Dermatitis—Capecitabine—prostate cancer	0.000123	0.00145	CcSEcCtD
Icosapent—Dyspepsia—Epirubicin—prostate cancer	0.000119	0.00141	CcSEcCtD
Icosapent—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000117	0.00139	CcSEcCtD
Icosapent—Constipation—Epirubicin—prostate cancer	0.000116	0.00137	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000114	0.00135	CcSEcCtD
Icosapent—Dyspepsia—Doxorubicin—prostate cancer	0.00011	0.00131	CcSEcCtD
Icosapent—Vomiting—Prednisone—prostate cancer	0.00011	0.00131	CcSEcCtD
Icosapent—Rash—Prednisone—prostate cancer	0.000109	0.00129	CcSEcCtD
Icosapent—Dermatitis—Prednisone—prostate cancer	0.000109	0.00129	CcSEcCtD
Icosapent—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000108	0.00128	CcSEcCtD
Icosapent—Constipation—Doxorubicin—prostate cancer	0.000107	0.00127	CcSEcCtD
Icosapent—Pruritus—Epirubicin—prostate cancer	9.59e-05	0.00114	CcSEcCtD
Icosapent—Pruritus—Doxorubicin—prostate cancer	8.87e-05	0.00105	CcSEcCtD
Icosapent—Vomiting—Epirubicin—prostate cancer	8.62e-05	0.00102	CcSEcCtD
Icosapent—Rash—Epirubicin—prostate cancer	8.55e-05	0.00101	CcSEcCtD
Icosapent—Dermatitis—Epirubicin—prostate cancer	8.54e-05	0.00101	CcSEcCtD
Icosapent—Vomiting—Doxorubicin—prostate cancer	7.98e-05	0.000945	CcSEcCtD
Icosapent—Rash—Doxorubicin—prostate cancer	7.91e-05	0.000937	CcSEcCtD
Icosapent—Dermatitis—Doxorubicin—prostate cancer	7.9e-05	0.000936	CcSEcCtD
Icosapent—FFAR1—Signaling Pathways—VEGFA—prostate cancer	6.26e-06	3.68e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—ERCC2—prostate cancer	6.26e-06	3.68e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—NPPA—prostate cancer	6.2e-06	3.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—HIST1H4H—prostate cancer	6.2e-06	3.64e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—STAT3—prostate cancer	6.2e-06	3.64e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PIK3CD—prostate cancer	6.19e-06	3.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	6.18e-06	3.63e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—NCOA1—prostate cancer	6.18e-06	3.63e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—NR3C1—prostate cancer	6.16e-06	3.62e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NCOA3—prostate cancer	6.15e-06	3.61e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	6.13e-06	3.6e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GSTA2—prostate cancer	6.11e-06	3.59e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—EP300—prostate cancer	6.1e-06	3.58e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—CYP19A1—prostate cancer	6.09e-06	3.58e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	6.04e-06	3.55e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ABCG5—prostate cancer	6.03e-06	3.54e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—SULT1A1—prostate cancer	6.03e-06	3.54e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—SRC—prostate cancer	5.93e-06	3.49e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GSTA1—prostate cancer	5.89e-06	3.46e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—RXRA—prostate cancer	5.87e-06	3.45e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—HPGDS—prostate cancer	5.87e-06	3.45e-05	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—PIK3CA—prostate cancer	5.85e-06	3.44e-05	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—PIK3CA—prostate cancer	5.85e-06	3.44e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	5.84e-06	3.43e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—NOS3—prostate cancer	5.84e-06	3.43e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CYP2C19—prostate cancer	5.83e-06	3.43e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GSTO1—prostate cancer	5.83e-06	3.42e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—HSD3B2—prostate cancer	5.83e-06	3.42e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NAT2—prostate cancer	5.83e-06	3.42e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—VEGFA—prostate cancer	5.78e-06	3.39e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—PPARA—prostate cancer	5.77e-06	3.39e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—MYC—prostate cancer	5.76e-06	3.38e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—TGFB1—prostate cancer	5.75e-06	3.38e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—STAT3—prostate cancer	5.72e-06	3.36e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.71e-06	3.36e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—GSTT1—prostate cancer	5.69e-06	3.34e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—ACHE—prostate cancer	5.69e-06	3.34e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—COMT—prostate cancer	5.66e-06	3.32e-05	CbGpPWpGaD
Icosapent—PPARG—Generic Transcription Pathway—MYC—prostate cancer	5.65e-06	3.32e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—EGFR—prostate cancer	5.64e-06	3.31e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—GSTP1—prostate cancer	5.63e-06	3.31e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CYP2A6—prostate cancer	5.63e-06	3.31e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	5.6e-06	3.29e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	5.6e-06	3.29e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYP2C18—prostate cancer	5.59e-06	3.28e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PLCB2—prostate cancer	5.59e-06	3.28e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—LRP2—prostate cancer	5.59e-06	3.28e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—ITPR1—prostate cancer	5.54e-06	3.26e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—P4HB—prostate cancer	5.48e-06	3.22e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—AKR1C3—prostate cancer	5.47e-06	3.22e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.45e-06	3.2e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PRKACB—prostate cancer	5.44e-06	3.2e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PIK3CB—prostate cancer	5.39e-06	3.17e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CYP17A1—prostate cancer	5.39e-06	3.17e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	5.37e-06	3.15e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PTGS2—prostate cancer	5.34e-06	3.14e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—SLC22A1—prostate cancer	5.33e-06	3.13e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—KRAS—prostate cancer	5.32e-06	3.13e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	5.31e-06	3.12e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—TGFB1—prostate cancer	5.3e-06	3.12e-05	CbGpPWpGaD
Icosapent—FADS1—Metabolism—AKT1—prostate cancer	5.28e-06	3.1e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—TGFBR1—prostate cancer	5.27e-06	3.1e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—B2M—prostate cancer	5.27e-06	3.1e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	5.27e-06	3.1e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—TYMS—prostate cancer	5.24e-06	3.08e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—ESR1—prostate cancer	5.23e-06	3.07e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—EGFR—prostate cancer	5.2e-06	3.06e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—SULT2A1—prostate cancer	5.19e-06	3.05e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	5.19e-06	3.05e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—AKR1C3—prostate cancer	5.19e-06	3.05e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—RPS19—prostate cancer	5.19e-06	3.05e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—GSTM1—prostate cancer	5.18e-06	3.04e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PRKACB—prostate cancer	5.16e-06	3.03e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NCOA2—prostate cancer	5.13e-06	3.02e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—MED12—prostate cancer	5.11e-06	3e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—LPL—prostate cancer	5.08e-06	2.98e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GNG5—prostate cancer	5.07e-06	2.98e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PPP3CA—prostate cancer	5.03e-06	2.96e-05	CbGpPWpGaD
Icosapent—PPARD—Gene Expression—MYC—prostate cancer	4.98e-06	2.93e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—KRAS—prostate cancer	4.91e-06	2.89e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—CYP1A1—prostate cancer	4.91e-06	2.88e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—SLC5A5—prostate cancer	4.9e-06	2.88e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—PIK3CA—prostate cancer	4.89e-06	2.87e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NCOA3—prostate cancer	4.88e-06	2.87e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PRKCZ—prostate cancer	4.87e-06	2.86e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—ERCC2—prostate cancer	4.87e-06	2.86e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	4.8e-06	2.82e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CYP2E1—prostate cancer	4.78e-06	2.81e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CALR—prostate cancer	4.78e-06	2.81e-05	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—AKT1—prostate cancer	4.78e-06	2.81e-05	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—AKT1—prostate cancer	4.78e-06	2.81e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—TP53—prostate cancer	4.73e-06	2.78e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NQO1—prostate cancer	4.73e-06	2.78e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—FGFR4—prostate cancer	4.7e-06	2.76e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PARP1—prostate cancer	4.7e-06	2.76e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—TH—prostate cancer	4.66e-06	2.74e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PTEN—prostate cancer	4.66e-06	2.74e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—HPGDS—prostate cancer	4.66e-06	2.74e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CALCA—prostate cancer	4.64e-06	2.73e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.63e-06	2.72e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYP2C19—prostate cancer	4.63e-06	2.72e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CYP3A4—prostate cancer	4.61e-06	2.71e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	4.59e-06	2.7e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—CREBBP—prostate cancer	4.58e-06	2.69e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—MTHFR—prostate cancer	4.57e-06	2.69e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CYP1B1—prostate cancer	4.53e-06	2.66e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GSTT1—prostate cancer	4.52e-06	2.65e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ACHE—prostate cancer	4.52e-06	2.65e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PPARA—prostate cancer	4.49e-06	2.64e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYP2A6—prostate cancer	4.47e-06	2.62e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—HSPA1A—prostate cancer	4.45e-06	2.61e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.45e-06	2.61e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—EP300—prostate cancer	4.44e-06	2.61e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—GGT1—prostate cancer	4.39e-06	2.58e-05	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	4.38e-06	2.58e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—AKR1C3—prostate cancer	4.34e-06	2.55e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—IL6—prostate cancer	4.33e-06	2.54e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NCOA1—prostate cancer	4.33e-06	2.54e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PRKACB—prostate cancer	4.32e-06	2.54e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—SERPINE1—prostate cancer	4.3e-06	2.52e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYP17A1—prostate cancer	4.28e-06	2.51e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CASP9—prostate cancer	4.27e-06	2.51e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CYP19A1—prostate cancer	4.26e-06	2.51e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—CAV1—prostate cancer	4.22e-06	2.48e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.22e-06	2.48e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PRKCQ—prostate cancer	4.14e-06	2.43e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—RXRA—prostate cancer	4.11e-06	2.42e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NCOA2—prostate cancer	4.08e-06	2.39e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.03e-06	2.37e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4e-06	2.35e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—IL6—prostate cancer	4e-06	2.35e-05	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—AKT1—prostate cancer	4e-06	2.35e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—COMT—prostate cancer	3.96e-06	2.33e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—GSTP1—prostate cancer	3.95e-06	2.32e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—FGF10—prostate cancer	3.93e-06	2.31e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—SLC5A5—prostate cancer	3.89e-06	2.28e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—ITPR1—prostate cancer	3.88e-06	2.28e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PIK3CG—prostate cancer	3.84e-06	2.26e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.82e-06	2.24e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYP2E1—prostate cancer	3.8e-06	2.23e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NQO1—prostate cancer	3.75e-06	2.21e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—TGFBR2—prostate cancer	3.74e-06	2.2e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—TH—prostate cancer	3.7e-06	2.17e-05	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—AKT1—prostate cancer	3.69e-06	2.17e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—ITPR1—prostate cancer	3.68e-06	2.16e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	3.68e-06	2.16e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—TYMS—prostate cancer	3.67e-06	2.15e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYP3A4—prostate cancer	3.66e-06	2.15e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—INS—prostate cancer	3.64e-06	2.14e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—GSTM1—prostate cancer	3.63e-06	2.13e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYP1B1—prostate cancer	3.6e-06	2.12e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—CREBBP—prostate cancer	3.56e-06	2.09e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—LPL—prostate cancer	3.56e-06	2.09e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GGT1—prostate cancer	3.49e-06	2.05e-05	CbGpPWpGaD
Icosapent—PPARD—Gene Expression—AKT1—prostate cancer	3.45e-06	2.03e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CYP1A1—prostate cancer	3.44e-06	2.02e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NCOA1—prostate cancer	3.43e-06	2.02e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—ERCC2—prostate cancer	3.41e-06	2e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYP19A1—prostate cancer	3.38e-06	1.99e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PIK3CD—prostate cancer	3.38e-06	1.98e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—LPL—prostate cancer	3.37e-06	1.98e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PDGFRB—prostate cancer	3.34e-06	1.96e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PIK3CA—prostate cancer	3.29e-06	1.93e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—RXRA—prostate cancer	3.27e-06	1.92e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—ERCC2—prostate cancer	3.23e-06	1.9e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—MTHFR—prostate cancer	3.2e-06	1.88e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—NOS3—prostate cancer	3.19e-06	1.87e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.18e-06	1.87e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—ERBB3—prostate cancer	3.16e-06	1.86e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—FGFR2—prostate cancer	3.16e-06	1.85e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—COMT—prostate cancer	3.15e-06	1.85e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PPARA—prostate cancer	3.14e-06	1.85e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GSTP1—prostate cancer	3.13e-06	1.84e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ITPR1—prostate cancer	3.08e-06	1.81e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—MTHFR—prostate cancer	3.04e-06	1.78e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.03e-06	1.78e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—TERT—prostate cancer	3.03e-06	1.78e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CAV1—prostate cancer	2.96e-06	1.74e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PIK3CB—prostate cancer	2.94e-06	1.73e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PTGS2—prostate cancer	2.92e-06	1.71e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—TYMS—prostate cancer	2.91e-06	1.71e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—HIF1A—prostate cancer	2.9e-06	1.7e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—GSTM1—prostate cancer	2.88e-06	1.69e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—LPL—prostate cancer	2.82e-06	1.66e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.82e-06	1.66e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CAV1—prostate cancer	2.8e-06	1.65e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYP1A1—prostate cancer	2.73e-06	1.6e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—MYC—prostate cancer	2.72e-06	1.6e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—ERCC2—prostate cancer	2.71e-06	1.59e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PIK3CG—prostate cancer	2.69e-06	1.58e-05	CbGpPWpGaD
Icosapent—PPARD—Metabolism—AKT1—prostate cancer	2.69e-06	1.58e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—BAD—prostate cancer	2.63e-06	1.55e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—APC—prostate cancer	2.55e-06	1.5e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—INS—prostate cancer	2.55e-06	1.5e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PTEN—prostate cancer	2.54e-06	1.49e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—MTHFR—prostate cancer	2.54e-06	1.49e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—EGF—prostate cancer	2.52e-06	1.48e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—IRS1—prostate cancer	2.52e-06	1.48e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CREBBP—prostate cancer	2.5e-06	1.47e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PPARA—prostate cancer	2.5e-06	1.47e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—GSK3B—prostate cancer	2.45e-06	1.44e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—EP300—prostate cancer	2.43e-06	1.43e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—INS—prostate cancer	2.42e-06	1.42e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PIK3CD—prostate cancer	2.37e-06	1.39e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CREBBP—prostate cancer	2.37e-06	1.39e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CAV1—prostate cancer	2.35e-06	1.38e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—MAP2K1—prostate cancer	2.26e-06	1.33e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PIK3CD—prostate cancer	2.24e-06	1.32e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.24e-06	1.32e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NOS3—prostate cancer	2.23e-06	1.31e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—SERPINE1—prostate cancer	2.22e-06	1.3e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—FGF2—prostate cancer	2.15e-06	1.26e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PIK3CG—prostate cancer	2.14e-06	1.26e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—NOS3—prostate cancer	2.12e-06	1.24e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PIK3CB—prostate cancer	2.06e-06	1.21e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—JAK2—prostate cancer	2.06e-06	1.21e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PTGS2—prostate cancer	2.04e-06	1.2e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—INS—prostate cancer	2.02e-06	1.19e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—MDM2—prostate cancer	2.01e-06	1.18e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CREBBP—prostate cancer	1.98e-06	1.16e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—ERBB2—prostate cancer	1.98e-06	1.16e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—PIK3CB—prostate cancer	1.96e-06	1.15e-05	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—AKT1—prostate cancer	1.89e-06	1.11e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PIK3CD—prostate cancer	1.88e-06	1.1e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CDKN1B—prostate cancer	1.83e-06	1.08e-05	CbGpPWpGaD
Icosapent—PPARG—Metabolism—PIK3CA—prostate cancer	1.79e-06	1.05e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PTEN—prostate cancer	1.78e-06	1.05e-05	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NOS3—prostate cancer	1.77e-06	1.04e-05	CbGpPWpGaD
Icosapent—PTGS2—Disease—CTNNB1—prostate cancer	1.73e-06	1.02e-05	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—EP300—prostate cancer	1.7e-06	9.99e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—CDKN1A—prostate cancer	1.69e-06	9.95e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—PTEN—prostate cancer	1.69e-06	9.93e-06	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PIK3CB—prostate cancer	1.64e-06	9.62e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—EP300—prostate cancer	1.61e-06	9.47e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—SRC—prostate cancer	1.57e-06	9.21e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—STAT3—prostate cancer	1.51e-06	8.88e-06	CbGpPWpGaD
Icosapent—PPARG—Metabolism—AKT1—prostate cancer	1.47e-06	8.62e-06	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PTEN—prostate cancer	1.41e-06	8.31e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—MYC—prostate cancer	1.4e-06	8.25e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—TGFB1—prostate cancer	1.4e-06	8.23e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—EGFR—prostate cancer	1.37e-06	8.07e-06	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—EP300—prostate cancer	1.35e-06	7.93e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—KRAS—prostate cancer	1.3e-06	7.62e-06	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PIK3CA—prostate cancer	1.26e-06	7.39e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—PIK3CA—prostate cancer	1.19e-06	7e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—IL6—prostate cancer	1.06e-06	6.2e-06	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—AKT1—prostate cancer	1.03e-06	6.04e-06	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PIK3CA—prostate cancer	9.98e-07	5.86e-06	CbGpPWpGaD
Icosapent—PTGS2—Disease—AKT1—prostate cancer	9.74e-07	5.72e-06	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—AKT1—prostate cancer	8.15e-07	4.79e-06	CbGpPWpGaD
